Nestigmine for abdominal distension

Reading File

Finding Sources

Searching PubMed

neostigmine colonic pseudo-obstruction ileus

Reading File

Here is a thorough summary of neostigmine for abdominal distension, drawn from Goodman & Gilman's, The Washington Manual, Current Surgical Therapy, and supported by recent meta-analysis.

Neostigmine for Abdominal Distension

Mechanism of Action

Neostigmine is a reversible acetylcholinesterase (anti-ChE) inhibitor. By inhibiting the breakdown of acetylcholine at the myenteric plexus, it increases cholinergic tone along the gut wall, stimulating peristalsis and restoring colonic motility. Among the anti-ChE agents, neostigmine is generally preferred for gastrointestinal indications.

Indications

Acute Colonic Pseudo-Obstruction (ACPO / Ogilvie's Syndrome) - the primary indication. ACPO is massive colonic distension without mechanical obstruction, most often seen in hospitalized elderly male patients after pelvic surgery, bony trauma, severe electrolyte disturbances, or with certain medications.
Postoperative paralytic ileus - when conservative measures (NPO, NG suction, ambulation, electrolyte correction) have failed.
Urinary bladder atony - used in a similar dose/manner.

Dosing

Setting	Route	Dose
Acute colonic distension (ACPO)	IV (slow)	2 mg IV over 3-5 minutes (some protocols use 2-5 mg IV over 1-5 min)
Postoperative paralytic ileus	Subcutaneous	0.5 mg SC as needed
Paralytic ileus (oral)	Oral (neostigmine bromide)	15-30 mg PO (onset 2-4 h)

Success is defined as passage of flatus, stool, or decreased abdominal distension. Peristaltic activity begins 10-30 minutes after parenteral administration.

A rectal tube or low enema may be used to assist evacuation.

Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 249
Washington Manual of Medical Therapeutics
Current Surgical Therapy 14e, p. 256

Place in Management of ACPO

The standard stepwise approach is:

Conservative measures first: NPO, fluid and electrolyte replacement, stop offending drugs (opioids, anticholinergics, TCAs, sedatives), encourage ambulation.
Neostigmine trial before colonoscopic decompression - in patients without contraindications, neostigmine is the preferred pharmacological bridge.
Colonoscopic decompression if neostigmine fails or is contraindicated (especially when cecal diameter approaches 12 cm).
Surgery (cecostomy, colectomy) for perforation, peritonitis, or ischemia.

A recent 2025 meta-analysis (PMID 40664115) directly compared neostigmine vs. colonoscopic decompression for ACPO not resolving with conservative measures, confirming neostigmine as first-line pharmacologic therapy.

Monitoring During Administration

Patient must be connected to continuous cardiac monitoring (ECG + pulse oximetry).
Atropine should be available at bedside.
Observe for: passage of flatus/stool and reduction of distension.

Side Effects

Side Effect	Notes
Bradycardia	Symptomatic; most common serious effect - have atropine ready
Abdominal cramping/pain	Due to increased gut motility
Excessive salivation	Muscarinic effect
Syncope	Vasovagal, related to rapid bowel decompression
Bronchospasm	Rare; caution in asthma/COPD

Contraindications

Neostigmine should NOT be used when:

Mechanical obstruction has not been excluded (essential before use)
Peritonitis is present
Bowel viability is in doubt
Intestinal or urinary bladder obstruction exists
Bowel dysfunction is from active inflammatory bowel disease
Evidence of perforation

Key Takeaway

Neostigmine is a well-established, effective treatment for acute colonic pseudo-obstruction and postoperative paralytic ileus. The standard IV dose is 2 mg slowly over 3-5 minutes under cardiac monitoring. It should be tried before colonoscopic decompression in appropriate patients and is contraindicated if mechanical obstruction has not been ruled out.

Does antiepileptics cause distension

Finding Sources

Searching the Web

antiepileptic drugs abdominal distension bloating constipation mechanism

Finding Sources

Reading File

Here is a complete answer based on textbook data and clinical evidence:

Do Antiepileptics Cause Abdominal Distension?

Yes - several antiepileptic drugs (AEDs) can cause or contribute to abdominal distension, mainly through slowing gut motility (constipation, ileus) and direct GI irritation causing gas and bloating. The Washington Manual specifically lists AEDs as drugs that can slow GI motility and contribute to distension - and in fact, stopping offending drugs (including sedatives and certain AEDs) is a core step in managing ACPO.

Mechanisms by Which AEDs Cause Distension

1. Anticholinergic / Reduction of GI Motility

Many older AEDs have anticholinergic or anti-autonomic properties that reduce peristalsis, slow colonic transit, and lead to constipation and gas accumulation. This is the most important mechanism.

2. Direct GI Irritation

Some AEDs irritate the gastric and intestinal mucosa, causing dyspepsia, bloating, and altered gut motility.

3. CNS-Mediated Gut Suppression

AEDs that depress the CNS broadly (e.g., via GABA enhancement) also suppress enteric nervous system activity, slowing motility.

Drug-by-Drug Breakdown

AED	GI / Distension-Related Effects	Mechanism
Valproate / Divalproex	Nausea, vomiting, dyspepsia, diarrhea, GI upset, weight gain	Direct GI irritation; most common in first month; enteric-coated forms better tolerated
Carbamazepine	Nausea, vomiting, gastric distress, constipation, diarrhea, anorexia	Anticholinergic-like + sodium channel blockade
Phenytoin	Nausea, constipation, GI upset	Anticholinergic effect
Gabapentin / Pregabalin	Diarrhea, bloating, weight gain; highest GI complication rate in polypharmacy	Unknown gut mechanism; calcium channel modulation
Topiramate	Nausea, weight loss, GI upset	Carbonic anhydrase inhibition, altered gut secretion
Ethosuximide	Nausea, diarrhea, weight gain, irritability	Calcium channel blockade
Phenobarbital / Barbiturates	Constipation, ileus in high doses	Broad CNS/ANS depression, reduced gut tone
Cannabidiol	Diarrhea, decreased appetite	Direct GI effect

Kaplan & Sadock's Synopsis of Psychiatry, p. 1988-1989
Lippincott Illustrated Reviews: Pharmacology, p. 654-655
PubMed study on GI effects of AEDs (PMID 21236703)

Key Clinical Points

Carbamazepine and phenytoin are the main culprits for constipation/distension due to anticholinergic and gut motility-slowing effects.
Gabapentin, when added to other AEDs, carries the highest frequency of GI complications in polypharmacy.
Valproate's GI effects are mostly nausea/dyspepsia rather than constipation; the enteric-coated (divalproex) formulation significantly reduces GI symptoms.
A large study of 100 intractable epilepsy patients found constipation in 26% of AED-treated patients, making it the third most common GI side effect after heartburn (34.6%) and nausea (33.7%).
The pathophysiology of chronic constipation literature explicitly lists antiepileptic drugs alongside antipsychotics and anti-Parkinson drugs as causes of drug-induced constipation via anticholinergic and dopaminergic actions.

Clinical Relevance to Abdominal Distension

In a patient with abdominal distension (e.g., ACPO / paralytic ileus), reviewing and stopping or reducing AEDs with anticholinergic properties (carbamazepine, phenytoin, phenobarbital) is part of conservative management - the same principle as stopping opioids and TCAs. This is why the Washington Manual's management of colonic distension specifically includes "withdrawal or dose reduction of medications that slow GI motility."

Bottom line: Carbamazepine and phenytoin are the most likely AEDs to cause or worsen abdominal distension through constipation. Gabapentin/pregabalin can cause bloating. Valproate causes GI upset but less commonly constipation/distension specifically.

This is a shared conversation. Sign in to Orris to start your own chat.